We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Selective Use of D-Dimer Test for Deep Vein Thrombosis

By LabMedica International staff writers
Posted on 30 Jan 2013
Print article
D-dimer testing based on clinical pretest probability for deep vein thrombosis (DVT) is safe and reduces diagnostic testing compared with checking all patients.

D-dimer testing is sensitive but not specific for DVT and changing the threshold level for a positive test result based on risk for DVT might improve the tradeoff between sensitivity and specificity and reduce the need for testing.

Scientists from McMaster University, (Hamilton, ON, Canada) randomly assigned 1,723 outpatients presenting for the first time with symptoms of DVT to selective testing for D-dimer for patients with low or moderate clinical pretest probability of DVT. Some patients with high clinical pretest probability had venous ultrasonograpy without D-dimer testing and some patients presenting with symptoms had uniform testing. The study groups were all consecutive symptomatic patients with a first episode of suspected DVT from five different hospitals.

Selective testing of 860 patients, defined as d-dimer testing for outpatients with low or moderate clinical pretest probability (C-PTP), where DVT excluded at d-dimer levels of equal to or less than 1.0 µg/mL, a low C-PTP or equal to or less than 0.5 µg/mL, moderate C-PTP. The groups who had venous ultrasonography without d-dimer testing for outpatients with high C-PTP and inpatients, or the 863 uniform testing defined as d-dimer testing for all participants where DVT was excluded at d-dimer levels of less than 0.51 µg/mL.

The incidence of symptomatic venous thromboembolism at three months was 0.5% in both study groups. Selective testing reduced the proportion of patients who required d-dimer testing by 21.8% and reduced the proportion that required ultrasonography by 7.6 % overall and by 21.0% in outpatients with low C-PTP. The authors concluded that a selective d-dimer testing strategy seems as safe as and more efficient than having everyone undergo d-dimer testing when diagnosing a first episode of suspected DVT. The study was published on January 15, 2013, in the journal Annals of Internal Medicine.

Related Links:

McMaster University



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.